Theodore Lawrence, M.D., Ph.D.

Theodore Lawrence, M.D., Ph.D.

As director of the University of Michigan Comprehensive Cancer Center, Dr. Theodore S. Lawrence is responsible for coordinating all cancer activities related to research and patient care. Lawrence, the Max S. Wicha M.D. Distinguished Professor of Oncology, is also chair of the Department of Radiation Oncology.

He is president of the Radiation Oncology Institute, which is devoted to supporting research in radiation oncology, immediate past president of the Society of Chairs of Radiation Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He is a member of the Institute of Medicine of the National Academy of Sciences. He has been president and chair of the board of the American Society of Radiation Oncology (ASTRO), chair of the National Cancer Institute Board of Scientific Councilors, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO). He has received the ASTRO Gold Medal, the highest award conferred by the society, an ASCO Statesman Award, and the 2014 Outstanding Investigator Award from the Radiological Society of North America.

Dr. Lawrence’s interests in the laboratory are focused on chemotherapeutic and molecularly targeted radiosensitizers. His clinical research combines these laboratory studies with conformal radiation guided by metabolic and functional imaging for the treatment of patients with gastrointestinal malignancies. He is the author of over 250 peer-reviewed publications and 30 book chapters. He is the editor of Translational Oncology, an editor of The Cancer Journal, the associate editor of Seminars in Radiation Oncology, and a senior editor for Cancer Research, and a past associate editor of the Journal of Clinical Oncology. He is an editor, along with Drs. Rosenberg and DeVita, of The Principles and Practice of Oncology.

Dr. Lawrence joined the faculty of the University of Michigan in 1987, following a fellowship in medical oncology and a residency in radiation oncology at the National Cancer Institute. He received his research degree in cell biology from the Rockefeller University in New York, followed by his medical degree from Cornell University and an internal medicine residency at Stanford University..

View Dr. Lawrence’s physician profile.

Eric R. Fearon, M.D., Ph.D.

Eric R. Fearon, M.D., Ph.D.
Deputy Director and Associate Director for Basic Science Research

Dr. Eric Fearon is the Emanuel N. Maisel professor of oncology and chief of the Division of Molecular Medicine and Genetics in the Department of Internal Medicine. As the Cancer Center’s deputy director for basic science research, he is responsible for coordinating studies of the mechanisms underlying cancer development and for the translation of laboratory observations to clinical applications in the diagnosis and management of cancer.

A nationally recognized expert in the field of cancer genetics, Dr. Fearon serves as co-director of the Cancer Center’s Genetics Research Program, which focuses on identifying the genetic alterations and gene expression changes that underlie the development of cancer, and on applying that knowledge to improve risk assessment, prevention, pre-symptomatic diagnosis, early detection, and therapy.

Dr. Fearon's research focuses on the nature and role of genetic alterations and gene expression changes in colorectal and other cancers of the gastrointestinal tract. He holds primary appointments in the Department of Internal Medicine and the Division of Medical Genetics, and joint appointments in the departments of Human Genetics and Pathology at the University of Michigan. He is an editorial board member or editor for a number of scientific journals.

Prior to joining the faculty at the University of Michigan in 1995, Dr. Fearon was an assistant professor at Yale University School of Medicine. He received his medical and research degrees and was a postdoctoral fellow at Johns Hopkins University in Baltimore.

View Dr. Fearon's research profile.

Kathleen Cooney photo

Kathleen Cooney, M.D.
Deputy Director for Clinical Services

Dr. Kathleen Cooney is the Frances and Victor Ginsberg Professor of Hematology/Oncology and a professor of internal medicine and urology at the University of Michigan Medical School. She is chief of the Division of Hematology/Oncology at the U-M Medical School and has served as interim medical director of the Cancer Center since 2011.

In her role as deputy director for clinical services, Dr. Cooney oversees and coordinates clinical activities across the spectrum of cancer care at U-M, including outpatient facilities, inpatient units and clinical programs at satellite locations. In addition, as well asacross a network of community partners.

Dr. Cooney is an internationally recognized physician scientist whose work on the identification and characterization of genetic factors impacting the development of prostate cancer has resulted in numerous significant contributions to the field. She serves as principal investigator or co-investigator on numerous NIH awards, including serving as co-director of the Cancer Center’s NCI SPORE grant in prostate cancer.  

A committed teacher and mentor, Dr. Cooney trains students at all levels in both laboratory and clinical settings.  Her clinical practice focuses on patients with bladder and/or prostate cancers as part of the Multidisciplinary Urologic Oncology Clinic at the Cancer Center.  She also serves as a staff physician at the Ann Arbor Veteran's Affairs Medical Center (VAMC).

Dr. Cooney received her medical degree at the University of Pennsylvania School of Medicine and completed residency training and a fellowship at the University of Michigan Medical School. She joined the U-M faculty in 1991.

Associate Director of Clinical Research


Moshe Talpaz, MD

Moshe Talpaz, M.D.
Associate Director of Translational Research

Moshe Talpaz, M.D., is the Alexander J. Trotman professor of leukemia research, and serves as associate chief of the Division of Hematology/Oncology.  A leading clinical investigator in hematologic malignancies. Dr. Talpaz focuses on the treatment of chronic myelogenous leukemia (CML), bringing special expertise in immunotherapy, cytokines and biologic response modifiers.

Internationally known for his role in the development of targeted cancer therapeutics, Dr. Talpaz pioneered the study of interferon in CML, which was the first line therapy for CML until the introduction of STI571 (Gleevec). As a pivotal member of the team that developed Gleevec, Dr. Talpaz was instrumental in bringing to market one of the most effective targeted treatments used to date in cancer care. As a leader in the development of novel therapeutics, Dr. Talpaz has applied his unique experience in the building of Phase I clinical trial programs to establishing the highly successful Ravitz Foundation Phase 1 / Translational Research Center at the Cancer Center.

Dr. Talpaz joined the U-M faculty in 2006 from M.D. Anderson Cancer Center in Houston, where he was professor of medicine and held the David Bruton Chair for Cancer Research. He has authored or co-authored nearly 400 journal articles and textbook chapters, and is a member of the American Society of Hematology and the NCCN Chronic Myelogenous Leukemia Guidelines Panel.

View Dr. Talpaz's physician profile.

Max S. Wicha, M.D.

Max S. Wicha, M.D.
Director Emeritus

Dr. Max S. Wicha founded the University of Michigan Comprehensive Cancer Center in 1987 and served as director for 27 years.

Dr. Wicha, professor of internal medicine, is nationally known for his research in the field of breast oncology, particularly the study of how breast cancer cells grow and metastasize, or spread. His lab was part of the team that first discovered stem cells in breast cancer, the first described in any human solid tumor.

Since then, Dr. Wicha has become one of the leading experts on cancer stem cells. In addition to his continued work on breast cancer stem cells, he has also led efforts within the Cancer Center to expand these findings into other tumor types. U-M researchers were first to discover stem cells in pancreatic, head and neck, and ovarian tumors and are focusing on cancer stem cells in virtually every cancer type, including colon, lung and thyroid tumors.

Dr. Wicha is an active clinician, specializing in the treatment of breast cancer patients. He is past chairman of both the Association of American Cancer Institutes and the National Cancer Institute's Cancer Center Support Review Committee.

Dr. Wicha joined the University of Michigan Medical School in 1980. From 1984 to 1993, he served as chief in the Division of Hematology/Oncology in the Department of Internal Medicine. Dr. Wicha received his medical degree from Stanford University and trained in internal medicine at the University of Chicago before moving to the National Cancer Institute, where he trained in clinical oncology and cancer biology.

View Dr. Wicha's physician profile.

Other Key Leaders:

Dean Brenner, M.D.
Director, Specialized Program of Research Excellence in Gastrointestinal Cancer

Arul Chinnaiyan, M.D., Ph.D.
Director, Specialized Program of Research Excellence in Prostate Cancer

Frank Manion, M.S.
Chief Informatics Officer

Jacques Nör, D.D.S., M.S., Ph.D.
Director, Specialized Program of Research Excellence in Head and Neck Cancer

Michael Sabel, M.D.
Chief of Surgical Oncology

Diane Simeone, M.D.
Director, Translational Oncology Program

Jeremy M.G. Taylor, Ph.D.
Associate Director, Biostatistics Unit

Alon Weizer, M.D., M.S.
Medical Director

Gregory T Wolf
Professor Emeritus of Otolaryngology-Head and Neck Surgery

-updated 09.2015

Return to top